Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs Post published:August 29, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains ‘Meme Stock’ Status; atai ‘Streamlilnes’ Pipeline; California Decrim. Bill Gutted Post published:August 19, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed CMO Turns Activist Shareholder; California Decrim. Bill Tentatively Clears Hurdle Post published:August 12, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies Post published:August 6, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing Post published:July 29, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms? Post published:July 15, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics Post published:July 11, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails? Post published:July 4, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees? Post published:June 27, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to Change Your Mind Comes to Netflix Post published:June 18, 2022 Post category:Psychedelic Bulletin